Cipla Ltd.

Cipla’s wholly owned subsidiary -- Cipla USA, Inc is recalling over 400 cartons of generic anti-cancer medication, Nilotinib Capsules, due to a manufacturing issue. Cipla USA, Inc has recalled Nilotinib Capsules in two strengths (150 mg and 200 mg). 

On February 18, 2026, Cipla USA, Inc had initiated the Class III voluntary recall. A Class III recall is initiated in a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.

Cipla is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).